Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: New stem cell product for ALS seeking approval in Canada
This week, BrainStorm Cell Therapeutics issued a news release announcing its intent to seek early regulatory approval to distribute its Amyotrophic Lateral Sclerosis (ALS) product to patients in Canada. This news was eagerly received by patient groups in Canada and internationally. ALS, also known as Lou Gehrig’s Disease, is a progressive neuromuscular disease in which […]
Right Turn: Checking in on Research2Reality
Research2Reality will soon be celebrating its 2nd anniversary. I first wrote about it when it launched and was excited by its mission to highlight the work of scientists across Canada, from a variety of disciplines, and make their research interesting and understandable to a non-expert audience. Through videos and blogs, Research2Reality is “shining a light […]
Right Turn: Good news for Canadian “butterfly boy”
Epidermolysis bullosa (EB) is a rare, and exceedingly painful, skin condition that I’ve written about here and here. Children with EB are sometimes referred to as “butterfly children” because their skin is said to be as fragile as a butterfly’s wings. The severity of the condition ranges from mild to fatal. Jonathan Pitre is a […]
Right Turn: Synthetic biology predicted to become a huge industry
There is a trend in the regenerative medicine field to include gene therapies when describing the work being performed by academics and industry, as in “cell and gene therapies.” The wider definition better reflects how the industry is evolving and acknowledges the dual focus. I expect the same may happen with synthetic biology’s role in […]